Frontiers in Pharmacology (Jul 2023)

Proton pump inhibitors may enhance the risk of digestive diseases by regulating intestinal microbiota

  • Liang Tian,
  • Chongfei Huang,
  • Wenkang Fu,
  • Long Gao,
  • Ningning Mi,
  • Mingzhen Bai,
  • Haidong Ma,
  • Chao Zhang,
  • Yawen Lu,
  • Jinyu Zhao,
  • Xianzhuo Zhang,
  • Ningzu Jiang,
  • Yanyan Lin,
  • Ping Yue,
  • Jinqiu Yuan,
  • Wenbo Meng,
  • Wenbo Meng

DOI
https://doi.org/10.3389/fphar.2023.1217306
Journal volume & issue
Vol. 14

Abstract

Read online

Proton pump inhibitors (PPIs) are the most used acid-inhibitory drugs, with a wide range of applications in the treatment of various digestive diseases. However, recently, there has been a growing number of digestive complications linked to PPIs, and several studies have indicated that the intestinal flora play an important role in these complications. Therefore, developing a greater understanding of the role of the gut microbiota in PPI-related digestive diseases is essential. Here, we summarize the current research on the correlation between PPI-related digestive disorders and intestinal flora and establish the altered strains and possible pathogenic mechanisms of the different diseases. We aimed to provide a theoretical basis and reference for the future treatment and prevention of PPI-related digestive complications based on the regulation of the intestinal microbiota.

Keywords